Baris Sonmez1, Umit Beden, Dilek Erkan. 1. Department of Ophthalmology, Ondokuzmayis University, Samsun, Turkey. drbarissonmez@gmail.com
Abstract
PURPOSE: To report regression of corneal stromal neovascularizations with the use of topical cyclosporine 0.05% in a corneal transplant patient performed for fungal corneal ulcer. DESIGN: Case report. METHODS: A 14-year-old boy treated for fungal corneal ulceration developed 360 degrees corneal stromal neovascularization peroperatively. Topical cyclosporine 0.05% was used to decrease the risk of rejection. RESULTS: The neovascularizations regressed totally within 2 months and no signs of graft rejection were present at 6 months follow up. CONCLUSION: Topical cyclosporine 0.05% may result in regression of stromal corneal neovascularizations and help to reduce the risk of graft rejection in selected cases.
PURPOSE: To report regression of corneal stromal neovascularizations with the use of topical cyclosporine 0.05% in a corneal transplant patient performed for fungal corneal ulcer. DESIGN: Case report. METHODS: A 14-year-old boy treated for fungal corneal ulceration developed 360 degrees corneal stromal neovascularization peroperatively. Topical cyclosporine 0.05% was used to decrease the risk of rejection. RESULTS: The neovascularizations regressed totally within 2 months and no signs of graft rejection were present at 6 months follow up. CONCLUSION: Topical cyclosporine 0.05% may result in regression of stromal corneal neovascularizations and help to reduce the risk of graft rejection in selected cases.
Authors: G L Hernández; O V Volpert; M A Iñiguez; E Lorenzo; S Martínez-Martínez; R Grau; M Fresno; J M Redondo Journal: J Exp Med Date: 2001-03-05 Impact factor: 14.307
Authors: Halil Ibrahim Onder; Mesut Erdurmus; Yasin Yücel Bucak; Hüseyin Simavli; Murat Oktay; Ahmet Sahap Kukner Journal: Int J Ophthalmol Date: 2014-04-18 Impact factor: 1.779